The company noted it reduced the list price of Symbicort at the start of this year. The change comes amid increasing attention and criticism about the cost of inhalers. The four major ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper ... with a fast action, in a single inhaler. A Viatris spokesperson said: "Viatris obviously ...

Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...